Evidence map›Paper›PMID 39337508›Full record

ArticleInternational journal of molecular sciences2024

Predicting Antidiabetic Peptide Activity: A Machine Learning Perspective on Type 1 and Type 2 Diabetes.

Kaida Cai, Zhe Zhang, Wenzhou Zhu, Xiangwei Liu, Tingqing Yu, Wang Liao

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kaida CaiDepartment of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing 210009, China.ORCID 0000-0003-2262-3869
Zhe ZhangDepartment of Statistics and Actuarial Science, School of Mathematics, Southeast University, Nanjing 211189, China.
Wenzhou ZhuDepartment of Statistics and Actuarial Science, School of Mathematics, Southeast University, Nanjing 211189, China.
Xiangwei LiuDepartment of Statistics and Actuarial Science, School of Mathematics, Southeast University, Nanjing 211189, China.
Tingqing YuKey Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China.
Wang LiaoKey Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China.ORCID 0000-0001-8319-2199

Funding

Fundamental Research Funds for the Central Universities 2242023R40055National Natural Science Foundation of China 12301334National Natural Science Foundation of China 82103834Natural Science Foundation of Jiangsu Province BK20230804Young Elite Scientists Sponsorship Program by CAST 2021QNRC001
6 · The paper itself

Abstract

Diabetes mellitus (DM) presents a critical global health challenge, characterized by persistent hyperglycemia and associated with substantial economic and health-related burdens. This study employs advanced machine-learning techniques to improve the prediction and classification of antidiabetic peptides, with a particular focus on differentiating those effective against T1DM from those targeting T2DM. We integrate feature selection with analysis methods, including logistic regression, support vector machines (SVM), and adaptive boosting (AdaBoost), to classify antidiabetic peptides based on key features. Feature selection through the Lasso-penalized method identifies critical peptide characteristics that significantly influence antidiabetic activity, thereby establishing a robust foundation for future peptide design. A comprehensive evaluation of logistic regression, SVM, and AdaBoost shows that AdaBoost consistently outperforms the other methods, making it the most effective approach for classifying antidiabetic peptides. This research underscores the potential of machine learning in the systematic evaluation of bioactive peptides, contributing to the advancement of peptide-based therapies for diabetes management.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Hypoglycemic AgentsMachine LearningPeptidesSupport Vector MachineHumansHypoglycemic AgentsPeptidesantidiabetic peptidesclassificationdiabetesfeature selectionmachine learning

Identifiers

PMID39337508
PMCPMC11432216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.